Based on the key measurements obtained from ATyr Pharma,'s financial statements, aTyr Pharma, is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, ATyr Pharma,'s Other Current Assets are relatively stable compared to the past year. As of 11/28/2024, Non Currrent Assets Other is likely to grow to about 139 K, while Short and Long Term Debt Total is likely to drop slightly above 8.3 M. Key indicators impacting ATyr Pharma,'s financial strength include:
Investors should never underestimate ATyr Pharma,'s ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor ATyr Pharma,'s cash flow, debt, and profitability to make informed and accurate decisions about investing in aTyr Pharma,.
Net Income
(52.91 Million)
ATyr
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Other Non Cash Items
Capital Expenditures
End Period Cash Flow
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Total Cash From Operating Activities
Change To Account Receivables
Issuance Of Capital Stock
Net Income
Total Cash From Financing Activities
Other Current Assets
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Lease Obligations
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Capital Stock
Net Working Capital
Short Term Debt
Common Stock
Depreciation And Amortization
Selling General Administrative
Selling And Marketing Expenses
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Minority Interest
Probability Of Bankruptcy
Understanding current and past ATyr Pharma, Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of ATyr Pharma,'s financial statements are interrelated, with each one affecting the others. For example, an increase in ATyr Pharma,'s assets may result in an increase in income on the income statement.
Comparative valuation techniques use various fundamental indicators to help in determining ATyr Pharma,'s current stock value. Our valuation model uses many indicators to compare ATyr Pharma, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ATyr Pharma, competition to find correlations between indicators driving ATyr Pharma,'s intrinsic value. More Info.
aTyr Pharma, is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . At this time, ATyr Pharma,'s Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value ATyr Pharma, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
aTyr Pharma, Systematic Risk
ATyr Pharma,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ATyr Pharma, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on aTyr Pharma, correlated with the market. If Beta is less than 0 ATyr Pharma, generally moves in the opposite direction as compared to the market. If ATyr Pharma, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one aTyr Pharma, is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ATyr Pharma, is generally in the same direction as the market. If Beta > 1 ATyr Pharma, moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in ATyr Pharma, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ATyr Pharma,'s growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of ATyr Pharma, growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of ATyr Pharma, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of aTyr Pharma,. We use our internally-developed statistical techniques to arrive at the intrinsic value of aTyr Pharma, based on widely used predictive technical indicators. In general, we focus on analyzing ATyr Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ATyr Pharma,'s daily price indicators and compare them against related drivers.
When running ATyr Pharma,'s price analysis, check to measure ATyr Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma, is operating at the current time. Most of ATyr Pharma,'s value examination focuses on studying past and present price action to predict the probability of ATyr Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma,'s price. Additionally, you may evaluate how the addition of ATyr Pharma, to your portfolios can decrease your overall portfolio volatility.